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1. Introduction 
A model to account for receptor-mediated biological 
effects of hormones, neurotransmitters and drugs 
was first proposed by Clark [I ]. This model is based 
on the assumptions that the interaction between 
ligand and receptor is reversible and that biological 
activity is proportional both to the number of occu- 
pied receptors and to the intrinsic activity of the 
ligand. Despite its simplicity, there are many experi- 
mental systems which behave according to the pre- [Pi R] 
dictions of Clark's theory. However, in many other [Pi] [R] 
systems the experimental data do not fit this model. 
Therefore, numerous additional models have been 
proposed to account for such observations. Most, if 
not all, models invoke mechanisms, described as com- 
plex multistep rocesses of coupling between ligand 
binding and biological activity (review [2]). By con- 
trast, little attention has been paid to the ligand itself. 
Heterogeneity of ligand-binding equilibrium constant 
has been acknowledged but only as a possible cause 
of artefacts in binding studies [3,4]. In no case has 
the direct consequence of ligand heterogeneity on its 
biological activity been clearly established. 
Here, we study, on a theoretical basis, the receptor- 
mediated effects of ligands heterogenous with respect 
to binding equilibrium constant and intrinsic biologi- 
n cal activity. We demonstrate hat, reacted with such r = Z 
ligands, systems for which the response to ligand is i = 1 
proportional to receptor occupancy are able to mimic 
systems for which coupling between ligand binding 
and biological effect is not linear. 
2. Mathematical formulation of the model 
ligands denoted P1 . . . . .  Pi . . . . .  Pn, are reversibly 
bound by a single order of univalent and independent 
binding sites denoted R, according to the following 
reaction equation: 
Pi + R ~-7-~ P iR , i  = 1 , . . .  ,n (1) 
At equilibrium the system is described by the law of 
mass action: 
-K i ,  i= 1 . . . . .  n (2) 
where K i is the binding equilibrium constant and [Pi], 
JR] and [Pi R] are the concentrations of free Pi, free 
R and Pi bound to R, respectively. Conservation of 
reactants i expressed by: 
[Pi]T = [Pi] + [PiR], i= 1 . . . . .  n (3) 
n 
[R]T = [R] + i~l  [PiR] (4) 
where [Pi]T and [R] T are the total concentrations of
Pi and R. Accordingly, the fractional receptor occu- 
pancy is: 
[Pi R ] / [R] T (5) 
If we assume that the biological activity, denoted Ai, 
displayed by Pi is proportional to the number of 
receptor sites occupied by Pi and to its intrinsic activ- 
ity, denoted Li: 
Let assume that n different orders of univalent Ai=L i [P iR] , i=  1 . . . . .  n (6) 
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the activity yielded by the heterogenous ligand is 
therefore: 
n 
A=ZA i 
i= l  
(7) 
I fA  M is assumed to be the activity by the heteroge- 
nous ligand at infinite dose, the fractional biological 
activity is: 
n 
a =A/A  M = i~=lAi/A M (8) 
Calculations have been performed according to 
[5 -7] .  The computer program, written in BASIC has 
been executed on a Hewlett-Packard HP 30 desk-top 
calculator and the curves have been plotted automat- 
ically by a Hewlett-Packard plott ing machine. 
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Fig.1. Binding isotherms and Scatchard plots of an hetero- 
genous ligand and its components in the case ofn = 2. The 
total receptor concentration is [R ] T = 10; the binding equili- 
brium constants are KI = 1 and K 2 = 10; the P 1 to P~ concen- 
tration ratio is [P~ ] T/[P2 ] T = 10. (A) Fractional receptor 
occupancy by the heterogenous ligand (P~ +P2) and each of 
its two components (P~ and P2) as a function of the hetero- 
genous ligand concentration ([P~ ] T + [P2 ] T ). (B) Plot ofP 1 
bound to free ratio ([PtR]/[P~ ]) as a function of bound P1 
([P1R]). (C) Plot ofP 2 bound to free ratio ([P2R]/[P:]) as a 
function of bound P2 ([P2R]) • (D) Plot of the heterogenous 
ligand bound to free ratio (([P1R] + [P:R])/([p I ] + [P2]) as 
a function of bound ligand ([P1R] + [p2R])). 
3. Results 
When the ligand is homogenous with respect o its 
binding equil ibrium constant and intrinsic activity 
(n = 1) the system behaves trictly according to Clark's 
theory and the biological activity is proportional to 
receptor occupancy (not shown). 
When n = 2, the binding isotherms (f ig.lA) may be 
a bell-shaped curve as for P1 or a sigmoid curve as for 
P2 and P1 +/°2. The Scatchard plots of the binding 
data show a downward concavity forP1 (fig.1 B) which 
could suggest positive cooperativity [2], and an 
upward concavity forP2 ( f ig . lC)which could suggest 
either receptor heterogeneity ornegative cooperativity 
[2]. In contrast, the Scatchard plot for binding of the 
heterogenous ligand (P1 +/2)  is linear (f ig.lD) as pre- 
dicted by Clark's theory. Depending on the parameters 
assigned to the heterogenous ligand, the dose-act iv i ty 
profiles may appear as sigmoid or biphasic curves 
(fig.2). Biphasic curves are generally ascribed to sepa- 
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Fig.2. Dose-activity profiles of an heterogenous ligand in the 
case ofn = 2. The total receptor concentration is [R] T = 10; 
the intrinsic activities are L~ = 1 and L 2 = 0. (A) Effect of 
variation of P~ to P~ concentration ratio; K 1 = 1 and K 2 = 10. 
(B) Effect of variation of K~; K 1 = 1 and [PI]T/[P2]T = 10. 
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Fig.3. Fractional receptor occupancy (.-.) as defined by eq. 
(5) and fractional biological activity ( - - )  as defined by eq. 
(8) as a function of total heterogenous ligand concentration 
in the case ofn = 2. The total receptor concentration is 
[R] T = 10; the intrinsic activities are LI = 1 and L 2 = 0; the 
PI :P2 concentration ratio is [P~ ] T/[P~ ] T = 0.1 ; the binding 
equilibrium constant forP 2 is K 2 = 0.1 ; (A) K 1 = 0.01; (B) 
K~ = 1. 
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Fig.4. Dose-activity profiles of an heterogenous ligand (n = 2) 
in the presence of varying amount of an homogenous ligand 
Pr  The total receptor concentration is [R] T = 10; the intrin- 
sic activities are L 1 = 1, L ~ = 0 and L 3 = 1 ; the binding equili- 
brium constant ofP 3 is K 3 = 100. (A) The P1 t°P2 concen- 
tration ratio is [PI l T/[P2 ] T = 0.01, Ka = 100 and K 2 = 1. 
(B) [P1]T/[P2]T = 10,KI = 1 andK 2 = 10. 
rate receptors, multisubsite receptors, receptor cross- 
linking, receptor desensitization or exhaustion of  the 
response system [2]. Considering the sigmoid curves, 
the absence of  proport ional i ty between receptor 
occupancy and biological activity as shown in fig.3, 
could be ascribed to positive or negative cooperativity 
or to complex allosteric effects [2]. 
In the presence of  an homogenous ligand, the dose-  
activity profiles of  an heterogenous ligand may mimic 
the effect of  a partial agonist of  the homogenous 
ligand (fig.4A). In other cases, the dose-act iv i ty  pro- 
files may exhibit a maximum (fig.4B). It is worth 
noting that the heterogenous ligand may exert stimu- 
latory, inhibitory or no effect depending on the char- 
acteristics and relative concentrations of  both the 
homogenous and the heterogenous ligand. 
When the ligand heterogeneity increases, the geo- 
metric patterns of  the binding isotherms and the 
dose-act iv i ty  profiles may become very complex, 
showing various numbers of  maxima, inflection points 
and plateaus (not shown). 
4. Discussion 
The main purpose of  this paper is to demonstrate 
that ligands, heterogenous with respect o binding 
equil ibrium constant and intrinsic biological activity, 
may generate complex binding isotherms and dose-  
activity profiles. Reacted with such ligands, systems 
which behave according to the very simply hypothesis 
of  Clark's model  [ 1 ], may mimic systems which 
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require far more sophisticated hypotheses for inter- 
pretation [2]. 
M r and/or biological activity heterogeneity among 
glycoprotein hormones i now well documented 
[8-12].  Antibodies directed against hormone recep- 
tors are being extensively studied [13-16]. The heter- 
ogeneity of such polyclonal antibodies and hormone 
preparations is well recognized. Nevertheless, the 
direct consequences of ligand heterogeneity on bind- 
ing and biological activity, are generally ignored in 
the interpretation f the data. 
This model provides a simple and plausible mecha- 
nism which may explain many properties of ligands 
which can be reasonably suspected to be heterogenous. 
However, ligand heterogeneity does not preclude 
complex mechanisms of coupling between ligand 
binding and biological activity. 
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